ARS Pharmaceuticals, Inc. (SPRY)
5.62
-0.05
(-0.88%)
USD |
NASDAQ |
Sep 04, 16:00
5.62
0.00 (0.00%)
After-Hours: 20:00
ARS Pharmaceuticals Research and Development Expense (Quarterly) : 4.698M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 4.698M |
| March 31, 2026 | 4.336M |
| December 31, 2025 | 3.443M |
| September 30, 2025 | 2.751M |
| June 30, 2025 | 4.035M |
| March 31, 2025 | 2.952M |
| December 31, 2024 | 3.027M |
| September 30, 2024 | 4.423M |
| June 30, 2024 | 6.896M |
| March 31, 2024 | 5.234M |
| December 31, 2023 | 3.404M |
| September 30, 2023 | 3.002M |
| June 30, 2023 | 7.308M |
| March 31, 2023 | 6.552M |
| Date | Value |
|---|---|
| December 31, 2022 | 4.70M |
| September 30, 2022 | 3.893M |
| June 30, 2022 | 4.35M |
| March 31, 2022 | 5.423M |
| December 31, 2021 | 15.68M |
| September 30, 2021 | 15.44M |
| June 30, 2021 | 17.54M |
| March 31, 2021 | 12.05M |
| December 31, 2020 | 8.648M |
| September 30, 2020 | 6.20M |
| June 30, 2020 | 4.988M |
| March 31, 2020 | 4.275M |
| December 31, 2019 | 6.273M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Passage Bio, Inc. | 3.343M |
| Vertex Pharmaceuticals, Inc. | 993.80M |
| Capricor Therapeutics, Inc. | 28.57M |
| Kyntra Bio, Inc. | 6.821M |
| Zentalis Pharmaceuticals, Inc. | 35.16M |